Ipamorelin vs Sermorelin
A side-by-side research comparison of Ipamorelin and Sermorelin across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Ipamorelin | Sermorelin |
|---|---|---|
| Full name | Ipamorelin (Selective GH Secretagogue) | Sermorelin Acetate (GHRH 1-29) |
| Category | Growth Hormone | Growth Hormone |
| Status | Research compound | Previously FDA-approved (discontinued 2008) |
| Mechanism | Selectively activates GHSR on pituitary somatotrophs. Unlike GHRP-6 and hexarelin, does not significantly activate ACTH or prolactin-releasing pathways. | Binds GHRH receptors on anterior pituitary via cAMP-PKA pathway. Preserves natural feedback regulation and pulsatility unlike exogenous HGH. |
| Molecular weight | 711.9 Da | 3,358 Da |
| Half-life | 2 hours | 10-20 minutes |
| Bioavailability | High (SubQ) | Moderate (SubQ) |
| Typical dose | 100-300 mcg | 200-300 mcg |
| Frequency | 1-3x daily | Once daily before bed |
| Route | Subcutaneous injection | Subcutaneous injection |
Ipamorelin reported benefits
- Clean GH release
- No cortisol or prolactin increase
- Improved sleep
- Fat loss
- Joint support
- Anti-aging benefits
Sermorelin reported benefits
- Natural GH pulsatility preserved
- Improved sleep quality
- Body composition improvement
- Skin elasticity
- Long safety record
Related comparisons
Research and educational reference only. Not medical advice.